Mizuho Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Hold Rating, Announces Target Price $3
Cautious Optimism Amidst Uncertainty: Assessing Amylyx Pharmaceuticals' Future Prospects
Analysts Conflicted on These Healthcare Names: Amylyx Pharmaceuticals Inc (AMLX), Taysha Gene Therapies (TSHA) and Lexeo Therapeutics, Inc. (LXEO)
Bank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration
We Think Amylyx Pharmaceuticals (NASDAQ:AMLX) Can Easily Afford To Drive Business Growth
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
